Analyst Ratings February 18, 2026

Canaccord lifts Kenvue price target to $18 after mixed Q4 results; Hold rating retained

Analyst tweak follows earnings that show modest growth but mixed metric outcomes amid pending Kimberly-Clark acquisition

By Derek Hwang KVUE KMB
Canaccord lifts Kenvue price target to $18 after mixed Q4 results; Hold rating retained
KVUE KMB

Canaccord Genuity increased its 12-month price objective on Kenvue Inc. to $18 from $17 while keeping a Hold rating. The consumer health company reported fourth-quarter and fiscal 2025 results that contained a mix of beats and misses versus different Street expectations, and management declined to host an analyst call because of the pending takeover by Kimberly-Clark. Canaccord and other market observers note the close linkage between Kenvue shares and Kimberly-Clark shares given the structure of the acquisition consideration.

Key Points

  • Canaccord raised its price target on Kenvue to $18 from $17 and maintained a Hold rating; company valuation metrics show a P/E of 24.82 and a PEG of 0.7.
  • Kenvue reported Q4/fiscal 2025 sales up 3.2% year-over-year with organic sales growth of 1.2%; adjusted EPS was $0.27, which compared differently against multiple Street expectations.
  • The outcome and near-term share performance are tied to the pending Kimberly-Clark acquisition, which calls for $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share and is expected to close in the second half of 2026.

Canaccord Genuity raised its price target on Kenvue Inc. (NYSE:KVUE) to $18 from $17 while maintaining a Hold recommendation on the stock. According to InvestingPro data cited with the company update, Kenvue is trading at a price-to-earnings ratio of 24.82 and a PEG ratio of 0.7, metrics the firm characterized as indicating a reasonable valuation relative to the company's projected growth.

The consumer health company released fourth-quarter and full fiscal 2025 results Monday after the close. On a headline basis, Kenvue reported sales that increased 3.2% year-over-year, a figure that compares to a Street sales estimate of 0.4%. On an organic basis, sales rose 1.2% year-over-year.

The company said all business segments contributed growth in the fourth quarter. Kenvue reported adjusted earnings per share of $0.27 for the quarter; depending on the referenced consensus, that figure represented both an upside and a shortfall. In one comparison noted in published data, adjusted EPS of $0.27 exceeded a Street estimate of $0.22. In another summary of analyst expectations, the same $0.27 was reported as below an anticipated $0.33.

Revenue for the quarter was reported at $3.78 billion, which was lower than a different consensus estimate of $4.11 billion despite the year-over-year 3.2% increase. Kenvue disclosed organic sales growth of 1.2%, with price and mix contributing 2.3% while volumes declined 1.1%.

Management called out two headwinds facing the business in the quarter: lower-than-normal seasonal illness rates and inventory reductions by retail customers. The company also saw category-level volume weakness, with self-care volumes down 3.1% and skin health and beauty volumes declining 0.8%.

Kenvue did not host an analyst call alongside the results because of the outstanding acquisition by Kimberly-Clark. The transaction remains on track to close sometime in the second half of 2026, according to company statements. Management emphasized continued focus on disciplined execution in the run-up to the deal closing.

Canaccord commented that Kenvue's share performance is expected to remain closely linked to Kimberly-Clark's stock under the terms of the takeover. The deal consideration is structured as $3.50 in cash per Kenvue share plus 0.14625 Kimberly-Clark shares for each Kenvue share.

In other market developments, BofA Securities resumed coverage of Kenvue with no rating assigned, a move tied in public commentary to the pending acquisition. The combination of mixed top-line and bottom-line comparisons to various analyst expectations, inventory movements at retailers, and soft category volumes illustrate the operational and market context as Kenvue moves through the transaction process.


Contextual note: The results encompass a mixture of metrics that both outperformed and underperformed different Street estimates. The company reported a year-over-year improvement in sales, positive contributions from pricing and mix, and simultaneous volume weakness in key consumer categories.

Risks

  • Acquisition timing and share-price linkage - Kenvue's market value is likely to track Kimberly-Clark's stock because of the deal mechanics, creating exposure to fluctuations in Kimberly-Clark's share price; this affects equity investors and M&A markets.
  • Demand and inventory pressures - Low seasonal illness rates and retailer inventory reductions have pressured volumes in consumer categories, impacting revenue and the consumer health sector.
  • Mixed analyst expectations and revenue shortfall versus some forecasts - Reported revenue of $3.78 billion fell below one consensus of $4.11 billion, and EPS compared variably to different Street estimates, introducing short-term earnings uncertainty for investors in health care products and consumer staples stocks.

More from Analyst Ratings

DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026 Truist Lifts Tandem Diabetes Price Target as Company Shifts Toward Pharmacy Model Feb 20, 2026 BWS Financial Boosts A10 Networks Price Target Citing AI-Driven Network Traffic Feb 20, 2026